Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roginolisib in advanced/metastatic uveal melanoma
NCT06717126Phase 2Active, not recruiting
- Sponsor
- iOnctura
- Start
- Feb 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of roginolisib in Uveal melanoma (UM) (3 arms), sponsored by iOnctura. Primary endpoint: Overall Survival at 96 weeks. Started Feb 2025; status: active, not recruiting.
02
Drugs
roginolisib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT06717126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06717126.